Skip to content

Manual Therapy for the Treatment of Athletic Pubalgia

Effects on Pain Anda Range of Motion of High Force Lateral Distraction Mobilization of the Hip in Athletes With Hip-related Groin Pain. A Randomized Controlled Trial.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05712486
Enrollment
36
Registered
2023-02-03
Start date
2023-02-01
Completion date
2025-10-30
Last updated
2026-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteitis Pubis

Brief summary

Athletic osteitis pubis is a high prevalent pathology among athletes, especially in those who make quick change of direction of the movement, like runners or footballers. Despite the fact that there is evidence about conservative treatments, there is a lack of evidence about manual therapy (MT) techniques applied in isolation and its consequences in pain and range of movement. The investigators decided to conduct a randomized controlled trial to compare the effects of a MT technique with placebo technique.

Interventions

OTHERHigh force hip Lateral distraction

Hip lateral distraction in adjusted position of maximun flexion and internal rotation, with neutral position of abduction/adduction applying high force of distraction.

OTHERPlacebo force hip lateral distraction

Hip lateral distraction in adjusted position of maximun flexion and internal rotation, with neutral position of abduction/adduction applying placebo force of distraction.

Sponsors

University of Valladolid
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Double- blind

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Athletes diagnosed with osteitis pubis stage 1 with at least 3 months of evolution. * Internal rotation ROM limited. * Positive provocation pain tests.

Exclusion criteria

* Pain due to intraarticular hip pathology. * Hip pain due to inflamatory diseases. * Previous surgical interventions in hip, pelvis or lumbar spine. * MRI results or provocation pain tests inconcluyent.

Design outcomes

Primary

MeasureTime frameDescription
Actual PAINBaselineactual pain reported by the patient using visual analog scale (VAS) from 0 to 10, in which higher scores are worse.
Last week PAINBaselinepast week pain reported by the patient using visual analog scale (VAS) from 0 to 10, in which higher scores are worse.

Secondary

MeasureTime frameDescription
Range of Movement (ROM)BaselineHip ROM as described by Pua et al. (2008)
Pain in sport activitiesBaselineAppearance time of pain during activities
Pain intensity in pain provocation tests: Single adductor, squeeze and bilateral adductor testsBaselineAppearance of pain during or after the execution of Single adductor, squeeze and bilateral adductor tests. If pain appears it will be reported by the patient using visual analog scale (VAS) from 0 to 10, in which higher scores are worse.
Muscle functionBaselineVelocity (m/s), force (N) and power (W) evaluated for internal and external hip rotators with a rotary axis flywheel-encoder system.
Functional capacityBaselineEvaluated with a patient reported outcome questionnaire called Copenhagen Hip and Groin Outcome score (HAGOS) which assesses pain, symptoms, physical function in daily living, physical function in sport and recreation, participation in physical activities and hip and groin -related quality of life. For each item answer range from "never" to "always".
Treatment credibility and expectancyDay 1, before treatmentEvaluated with Credibility and expectancy Questionaire (CEQ) in which the patient answer question related to the expectations of the intervention. Higher values mean better expectations on the therapy.
Global Rating of Changeafter to two weeks of treatmentSubjective impression as described in GROC scale by Jaeschke, Singer \& Guyat (1989)
Group of treatment assignmentafter to two weeks of treatmentQuestion about which group of treatment was the patient assigned in.

Countries

Spain

Contacts

PRINCIPAL_INVESTIGATORSilvia Lahuerta Martín

University of Valladolid

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026